



21st October, 2022

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub: Compliance as per Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed the Related Party Transactions for the half year ended on 30-Sep-22.

Kindly take note of the above.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI
COMPANY SECRETARY

Encl : A/a

TORRENT PHARMACEUTICALS LIMITED

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,

www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.													
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee (Rs. in Crores)	Remarks on approval by audit committee	Value of transaction during the reporting period (Rs. in Crores)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments						
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance (Rs. in Crores)	Closing balance (Rs. in Crores)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)	Notes	
67	Heumann Pharma GmbH & Co Generica KG, Germany		Torrent Pharma (UK) Ltd (TPUK), UK		Fellow Subsidiary of Holding company	Loan			-	-	202.09	184.26					Loan	3.09%	5 years, extendable	Secured	Business Purpose		
68	Heumann Pharma GmbH & Co Generica KG, Germany		Torrent Pharma (UK) Ltd (TPUK), UK		Fellow Subsidiary of Holding company	Interest received			-	2.69	1.27	1.43											
69	Heumann Pharma GmbH & Co Generica KG, Germany		Torrent Pharma GmbH (TPG), Germany		Holding Company	Loan			-	20.34	-	20.03					Loan	0.99%	Working Capital Requirement (Short term)	Unsecured	Business Purpose		
70	Heumann Pharma GmbH & Co Generica KG, Germany		Torrent Pharma GmbH (TPG), Germany		Holding Company	Interest received			-	0.02	-	-											
71	Heunet Pharma GmbH, Germany		Heumann Pharma GmbH & Co Generica KG, Germany		Fellow Subsidiary	Loan			-	(40.68)	253.98	200.27					Loan	1.84%	Working Capital Requirement (Short term)	Unsecured	Business Purpose		
72	Heunet Pharma GmbH, Germany		Heumann Pharma GmbH & Co Generica KG, Germany		Fellow Subsidiary	Interest received			-	1.18	-	-											
73	Heumann Pharma GmbH & Co Generica KG, Germany		Torrent Pharma (UK) Ltd (TPUK), UK		Fellow Subsidiary of Holding company	Any other transaction	Expenses reimbursement		-	0.16	-	-											
74	Torrent Pharma GmbH (TPG), Germany		Heumann Pharma GmbH & Co Generica KG, Germany		Wholly owned subsidiary	Investment			-	-	31.04	31.04											
75	Torrent Pharma GmbH (TPG), Germany		Heunet Pharma GmbH, Germany		Wholly owned subsidiary	Investment			-	-	0.17	0.17											
76	TPL (Malta) Limited		Torrent Pharma (Malta) Limited		Wholly owned subsidiary	Investment			-	-	8.17	8.17											

@ excluding provision for gratuity and leave encashment, insurance premium for group personal accident and group mediclaim.

^ excluding Goods and Services Tax.

Remuneration for April-2022 to July-2022. Aman Mehta is appointed as a Director w.e.f. 01st August,2022 and remuneration of August and September 2022 has been disclosed as Remuneration to Key Management Personnel.